Detrusitol

Quick links to important sections

Detrusitol

Selected form

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Detrusitol

Property Description
Active ingredient Tolterodine (as Tolterodine tartrate)
Form Oral (Immediate-release tablets, Extended-release capsules)
Pharmacological class Antimuscarinic agent / Anticholinergic drug
General purpose Management of overactive bladder symptoms
Origin Synthetic compound

What is Detrusitol and its Composition?

Detrusitol is a brand name for a synthetic prescription medication used as a therapeutic agent for managing bladder symptoms. Its sole active component is Tolterodine, typically administered as Tolterodine tartrate. The drug is classified by its origin as a chemically synthesized compound. This single-ingredient product is formulated for oral administration, utilizing standard pharmaceutical excipients to create the final dosage forms. The chemical structure of Tolterodine represents a distinct synthetic composition.


Pharmacological Class, Forms, and General Purpose

Tolterodine belongs to the antimuscarinic agent group, placing it within the broader category of anticholinergic drugs. This pharmacological classification signifies that the substance is designed to selectively block the action of the neurotransmitter acetylcholine at specific muscarinic receptors. Tolterodine is a treatment option used to provide improvement in symptoms of urgency, frequency, and urge incontinence.

Detrusitol is supplied as an oral dosage form, available either as immediate-release tablets (IR) or as extended-release capsules (ER). The primary, general purpose of this medicine is to help manage symptoms associated with overactive bladder (OAB). By inhibiting the uncontrolled contractions of the detrusor muscle, Tolterodine acts to increase the functional bladder capacity, thereby providing the general benefit of alleviating the sudden, compelling urge to urinate.

What side effects are possible with Detrusitol?

Possible Side Effects and Safety Information

The safety profile for Detrusitol (Tolterodine) is primarily characterized by adverse reactions related to its antimuscarinic pharmacological action. Regulatory documents classify these potential effects based on their observed frequency in clinical studies.

Frequency-Classified Adverse Reactions

The most frequently documented effects, classified as Very Common (occurring in 1 or more in 10 patients) in official labeling, are dry mouth (xerostomia) and headache.

Common reactions (1 in 100 to less than 1 in 10) are documented across several System-Organ Classes (SOCs), most notably involving the Gastrointestinal System (e.g., constipation, abdominal pain, dyspepsia), the Nervous System (e.g., dizziness, somnolence), and Eye Disorders (e.g., dry eyes, abnormal vision). Other common effects include palpitations, hypertension, and fatigue.

Serious Adverse Reactions and Restrictions

Specific, clinically significant adverse reactions listed in regulatory texts include Anaphylactoid reactions (Uncommon) and Angioedema (Rare).

The medicine is subject to absolute restrictions (contraindications) for use in individuals with pre-existing conditions that may be worsened by antimuscarinic effects. These restrictions include urinary retention, uncontrolled narrow-angle glaucoma, myasthenia gravis, severe ulcerative colitis, and toxic megacolon.

Population-Specific Safety Considerations

Official safety notes advise that caution is required for patients with reduced hepatic function and for those with moderate to severe renal impairment. Additionally, co-administration with strong inhibitors of the enzyme CYP2D6 may necessitate careful consideration due to the potential for increased systemic exposure to Tolterodine.

Overdose and Emergency Response

Overdose with Detrusitol (Tolterodine) is defined by the official regulatory documents based on the presentation of acute anticholinergic effects. Documented clinical manifestations of overdose include micturition difficulties and accommodation disturbances, which reflect excessive antimuscarinic activity. Severe central nervous system effects are also documented, encompassing hallucinations, severe excitation, disorientation, and confusion.

Exposure to high doses is associated with documented risks to the cardiovascular system, specifically QT interval prolongation, and the potential for severe outcomes such as respiratory insufficiency and urinary retention.

Regulatory guidance mandates seeking immediate medical attention for any suspected overdose. Emergency services must be contacted immediately if the affected person has collapsed, had a seizure, is unresponsive, or is experiencing trouble breathing.

Official management procedures include initial decontamination measures such as gastric lavage and the administration of activated charcoal. Symptomatic and supportive treatment is the required general approach. For severe central anticholinergic effects, Physostigmine is listed as the targeted agent, and other targeted interventions, such as beta-blockers for tachycardia, are described for managing documented complications.

Therapeutic Uses of Detrusitol

What Detrusitol Treats: Main Uses and Benefits

Detrusitol, containing Tolterodine, is commonly used for the symptomatic management of problems associated with Overactive Bladder (OAB). The medication is relevant in clinical settings marked by the heightened patient distress caused by symptoms of increased neurological or muscular activity, which interfere with daily functioning. The medication's primary role is in symptomatic management, helping to address the functional instability that may lead to these distressing manifestations.


The drug is commonly used for managing the symptom clusters of urinary urgency, increased frequency (including nocturia), and urge incontinence. Providing supportive relief when symptoms interfere with routine activities helps ease the overall symptom burden and offers symptomatic relief that supports patients during episodes of heightened discomfort. The medication may support better comfort regarding the ability to store urine, which may be associated with longer, more manageable intervals between voiding.

“Tolterodine is commonly used when symptoms cluster into patterns requiring supportive management of urge incontinence episodes, addressing symptoms that create noticeable functional strain.”


Quick Fact: Relief for Overactive Bladder Symptoms

Detrusitol is applied in clinical settings that involve acute or unstable symptom patterns to provide support that helps ease the overall symptom burden associated with chronic OAB. The treatment may assist with maintaining functional stability and is relevant for patients experiencing recurrent or episodic manifestations of urgency, frequency, and involuntary leakage.

Regulatory References

  1. NIH MedlinePlus overview of Tolterodine

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Detrusitol (Tolterodine)

Detrusitol use is strictly defined by regulatory eligibility rules and is generally restricted to adult patients, including older adults. Use is contraindicated in patients with urinary retention, gastric retention, uncontrolled narrow-angle glaucoma, and known hypersensitivity to the drug substance.

Classification Population Rule
Absolute Contraindications Urinary Retention, Gastric Retention, Uncontrolled Glaucoma
Use Not Recommended Severe Hepatic Impairment, Extreme Renal Impairment, Pediatric Population
Conditional Use Severe Renal Impairment (CCr 10-30 mL/min), Mild-to-Moderate Hepatic Impairment
Reproductive Status Not recommended during Pregnancy or Breastfeeding

The drug is not recommended for use in children because safety and effectiveness have not been established in the pediatric population. Use requires caution in individuals with clinically significant bladder outflow obstruction, gastrointestinal obstructive disorders, or risk factors for QT prolongation. Conditional use in patients with compromised organ function requires restricted dosage as documented by regulatory agencies.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Detrusitol's interaction profile is primarily defined by how other medications affect its metabolism and by additive pharmacodynamic effects.

Pharmacokinetic Interactions

Detrusitol is metabolized mainly by the enzyme Cytochrome P450 2D6 (CYP2D6) and to a lesser extent by CYP3A4.

Interacting Medicine Category Example Medicines Listed in Regulatory Documents Regulatory Requirement
Potent CYP3A4 Inhibitors Ketoconazole, Clarithromycin, Ritonavir Mandatory dose reduction is required due to increased exposure to the active moiety.
Potent CYP2D6 Inhibitors Fluoxetine Close monitoring or dose adjustment may be necessary.

Individuals identified as CYP2D6 Poor Metabolizers are particularly susceptible to these interactions, experiencing significantly higher drug concentrations when potent CYP3A4 inhibitors are co-administered.


Pharmacodynamic Interactions

Interacting Medicine Category Implication for Concomitant Use
Other Anticholinergic Agents Use is discouraged due to the potential for excessive additive antimuscarinic effects.
QT-Prolonging Drugs Caution is advised; this includes Class IA (e.g., quinidine) and Class III (e.g., amiodarone) antiarrhythmics, due to the risk of additive effects on the heart's electrical conduction.

Warfarin and Combined Oral Contraceptives (Ethinyl Estradiol/Levonorgestrel) have been officially noted as not having a clinically significant interaction.

Mechanism of Action

The mechanism of Detrusitol, whose active ingredient is tolterodine, is based on its action as a competitive antagonist within the autonomic nervous system. The mechanism involves the drug acting as a competitive antagonist, modulating pathways associated with involuntary detrusor muscle contraction, specifically by targeting the muscarinic receptor system.


Molecular Blockade of Cholinergic Signaling

Tolterodine and its active metabolite (the 5-hydroxymethyl derivative) act by binding to the muscarinic receptors ( M2 and M3) on the detrusor smooth muscle wall. This antagonistic interaction prevents the binding of the neurotransmitter acetylcholine (ACh), thereby inhibiting the signal transduction that mediates muscle contraction. The combined action of the drug and its metabolite contributes to the overall duration of receptor blockade.


⬆️ Cascade to Increase Bladder Compliance

By interrupting the contraction signal at the receptor level, the drug modifies the early molecular steps that shape systemic physiological outcomes. This inhibition of contraction causes the detrusor muscle to relax, resulting in decreased intravesical pressure and increased functional bladder capacity. This modulation results in changes to the state of the targeted pathway, leading to altered muscle tone.

Dosage and Administration Information

How to Use Detrusitol: Official Administration Guidelines

Detrusitol (Tolterodine) is administered exclusively by the oral route using immediate-release (IR) tablets or extended-release (ER) capsules. The choice of formulation dictates the frequency and timing pattern of the medicine. The medication may be taken with or without food.


Standard Dosage Regimens

The standard dosing regimen is structured around achieving a 4 mg daily intake through different schedules.

Form Strength Frequency Standard Dose Pattern
IR Tablets 1 mg, 2 mg Twice daily (q12h) 2 mg twice daily (maximum 4 mg/day)
ER Capsules 2 mg, 4 mg Once daily 4 mg once daily (maximum 4 mg/day)

Administration Requirements and Dose Adjustments

Use of the extended-release capsule requires that the medication be swallowed whole with water; it must not be chewed, crushed, or opened, as this would compromise its delivery mechanism.

For patients with documented severe renal impairment or moderate hepatic impairment, the total daily dose should be reduced to a maximum of 2 mg (e.g., 1 mg twice daily for IR or 2 mg once daily for ER). If a dose is missed, it should be skipped, and the patient should resume the next scheduled dose at the usual time; doubling the dose is not permitted.

Treatment is typically used as part of a long-term plan, and its continued appropriateness should be re-evaluated by a healthcare provider after 2 to 3 months of use.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Detrusitol

Evidence for Overactive Bladder (OAB) Symptoms in Adults

Research on the active compound Tolterodine (the substance in Detrusitol) has primarily focused on its application in adults managing symptoms of Overactive Bladder (OAB). The foundational evidence base was developed through short-term Randomized Controlled Trials (RCTs) that included a comparison group receiving a placebo, often with a duration of around 12 weeks. These studies were used in research exploring how OAB symptoms, such as urgency, frequency, and urge incontinence, change over a defined time interval.

In these research settings, studies monitored various patient outcomes. Studies reported on the patterns observed during the study period, which included measurements of changes in the frequency of daily voiding and the number of incontinence episodes recorded in patient diaries. Research also examined measurements of physiological change, such as the maximum volume of urine the bladder was observed to hold during the study period.

Outcomes Examined in Clinical Trials

Research explored several ways to measure outcomes related to the intervention in OAB, moving beyond simple counts of episodes. Studies monitored functional measurements alongside patient-reported outcomes describing perceived discomfort. For instance, trials included urodynamic testing to monitor physiological strain related to involuntary bladder contractions.

Furthermore, applied in studies examining patient-reported experiences, researchers employed validated questionnaires to measure outcomes related to daily functioning and the degree of bother caused by the symptoms. This evidence contributes to understanding symptom patterns and helps contextualize how patients reported their experience during the study. While studies report how symptoms evolved in the observed populations, evidence quality varies across these different types of measured outcomes.

What Research Gaps and Uncertainty Exist

The evidence landscape is subject to several limitations. The follow-up durations were limited in the pivotal efficacy trials, meaning long-term outcomes are not well characterized. Findings were mixed or sometimes of lower certainty, particularly regarding the specific measurements of patient-reported quality of life, compared to the more objective measures of voiding frequency.

Another key limitation is that the results apply only to the populations studied, and evidence is limited for many specific subgroups, meaning data for certain subgroups remain insufficient. The research provides context but does not determine whether an individual will respond similarly, especially when symptoms are severe or accompanied by other health conditions.

Key Studies & References

  1. Tolterodine Tartrate Public Assessment Report (PAR) for Decentralised Procedure (European Regulatory Review)

Frequently Asked Questions (FAQ)

Common questions about Detrusitol (FAQ)


Q: Is Detrusitol the same as Detrol?

A: Yes, Detrol is a brand name used in some regions for the same active ingredient found in Detrusitol, which is tolterodine. Both Detrol and Detrusitol refer to the same medicine used to manage overactive bladder symptoms. This is common practice, as a single active compound may be marketed under different brand names internationally.


Q: Can Detrusitol affect my driving ability?

A: Official product information indicates that Detrusitol may cause side effects such as dizziness, somnolence (drowsiness), or blurred vision. These reported effects indicate that caution regarding driving or operating machinery may be warranted.


Q: What should I do if I notice an allergic reaction after taking Detrusitol?

A: Official guidance states the medicine should be stopped and immediate medical attention sought if signs of an allergic reaction appear. These signs may include hives, trouble breathing, or swelling of the face, mouth, or throat. Prompt action is necessary if these serious reactions are observed.


Q: Can men use Detrusitol, or is it only for women?

A: According to the official product information, Detrusitol is approved for the treatment of overactive bladder (OAB) symptoms in adult patients. This designation includes both men and women who have been diagnosed with the condition.


Q: What happens if I drink alcohol while taking Detrusitol?

A: Caution is advised when using alcohol. Since the medicine can cause dizziness and drowsiness as known side effects, the combination of alcohol and the medicine may result in increased effects on the central nervous system, such as greater dizziness or drowsiness.


Q: Is there a generic version of Detrusitol available?

A: Yes, regulatory agencies have approved generic versions of the active ingredient, tolterodine tartrate. Generic drugs contain the same active ingredient and are required by regulatory bodies to meet specific standards for quality and manufacturing consistency with the brand-name product.


Q: Is Detrusitol a controlled substance?

A: According to official regulatory classifications, the medicine is not a controlled substance under the US Controlled Substances Act (CSA) and similar international regulations.


Q: Are there any known interactions between Detrusitol and herbal remedies?

A: While standard regulatory documents list known interactions with many prescription drugs, official sources note that patients are generally advised to inform their healthcare provider about all other medicines, vitamins, and herbal products they use. This is because not all possible interactions can be documented in the standard prescribing information.


Q: Are there any common over-the-counter pain relievers that interact with Detrusitol?

A: Official prescribing information focuses on interactions with other medicines that affect certain liver enzymes, specifically CYP2D6 or CYP3A4 inhibitors. Official guidance recommends that patients discuss all prescription and over-the-counter medicines with their healthcare provider.


Q: Can older adults safely use Detrusitol, or are there special concerns?

A: The medicine is approved for use in all adults, including the elderly. However, regulatory reviews have noted post-marketing reports of potential side effects such as confusion, disorientation, and memory impairment in this population. For this reason, official safety information suggests that careful consideration is necessary.


Q: Does taking Detrusitol affect sleep?

A: Yes, official safety reviews have noted reports of insomnia, or the inability to sleep, as a possible event, though the overall frequency is not reliably determined from spontaneous reports. Additionally, drowsiness (somnolence) is listed as a common side effect in prescribing information.


Q: Why does Detrusitol sometimes cause blurred vision?

A: The active ingredient acts as an antimuscarinic, meaning it blocks signals in certain parts of the nervous system. In the eye, this action can affect the eye's ability to focus (accommodation), which may result in temporary blurred vision.


Q: Can Detrusitol be used by people who have high blood pressure?

A: The official prescribing information includes warnings that the medicine may pose a higher risk when used with certain medications, including some for high blood pressure. Regulatory information specifies that a healthcare provider should be aware of all existing conditions and medications for hypertension.


Q: Does Detrusitol interact with common allergy medications (antihistamines)?

A: Official documents advise against or discourage the use of Detrusitol with other anticholinergic agents. Since many common allergy medicines (antihistamines) have anticholinergic properties, combining them could potentially lead to excessive or additive side effects.


Q: Why do some people experience dizziness when starting Detrusitol?

A: The anticholinergic action of the medicine targets the nervous system and can cause central nervous system (CNS) effects. Official information attributes side effects like dizziness and drowsiness to this action.


Q: What if I take two doses of Detrusitol too close together by accident?

A: Official patient guidance states that if a person takes more than the prescribed amount of the medicine, immediate contact with a doctor or poison control center, or evaluation at a hospital emergency room, is necessary.


Q: Are there any known interactions with heart medications?

A: Caution is specifically advised in regulatory documents when Detrusitol is used with medicines that prolong the QT interval. This group includes certain antiarrhythmics (heart rhythm medicines) because there is a risk of additive effects on the heart's electrical conduction.


Q: Why is Detrusitol sometimes confused with other bladder drugs?

A: The confusion likely arises because Detrusitol belongs to the pharmacological class known as anticholinergics or urinary antispasmodics. Several other medicines used to treat overactive bladder symptoms belong to this same therapeutic group.


Q: Can Detrusitol affect my mental clarity or memory?

A: Regulatory reports detail post-marketing experiences where effects such as confusion, disorientation, and memory impairment were reported. Due to these reports, the prescribing physician may consider monitoring for cognitive changes.


Q: Is the medication known by different names internationally?

A: Yes, the active ingredient is known by multiple brand names globally. For instance, in addition to Detrusitol, it is commonly known as Detrol or Detrol LA in the US and other regions.

How should Detrusitol be stored and disposed of?

How to Store and Dispose of Detrusitol (Tolterodine Tartrate)

The storage requirements for Detrusitol vary depending on the dosage form, and all instructions are based strictly on regulatory labeling.

Requirement
Storage Temperature
IR Tablets: No special precautions are needed regarding temperature.
ER Capsules: Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F).
Protection
ER Capsules: Must be protected from light, extreme heat, and excessive moisture.
Child Safety
Both forms must be kept out of the sight and reach of children.

Unused or expired Detrusitol should be disposed of in accordance with local requirements. The official guidance recommends utilizing a drug take-back program if available. If a take-back program is unavailable, disposal must follow the specific instructions from the national health authority for household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Detrusitol found in:

A-Z Index: